Tagrisso is medicine for treating a lung cancer called non-small cell lung cancer (NSCLC) when the cancer is advanced or has spread.
It is used in patients who have mutations (changes) in a gene for a protein called EGFR. If a patient has mutations known as an ‘activating mutations’, Tagrisso is given as the first treatment. In patients with T790 mutation, the medicine may be given after other treatments.
It contains the active substance osimertinib.
Tagrisso : EPAR - Medicine overview (PDF/76.27 KB)
First published: 17/02/2016
Last updated: 07/09/2018
Tagrisso : EPAR - Risk-management-plan summary (PDF/152.27 KB)
First published: 30/11/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Carcinoma, Non-Small-Cell Lung
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
24/10/2019 Tagrisso - EMEA/H/C/004124 - II/0029
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
Tagrisso is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).